ABSTRACT

Introduction Congenital heart disease (CHD) is a major cause of infant mortality. Many infants with CHD require corrective surgery with most operations requiring cardiopulmonary bypass (CPB). CPB triggers a systemic inflammatory response which is associated with low cardiac output syndrome (LCOS), postoperative morbidity and mortality. Delivery of nitric oxide (NO) into CPB circuits can provide myocardial protection and reduce bypass-induced inflammation, leading to less LCOS and improved recovery. We hypothesised that using NO during CPB increases ventilator-free days (VFD) (the number of days patients spend alive and free from invasive mechanical ventilation up until day 28) compared with standard care. Here, we describe the NITRIC trial protocol.

Methods and analysis The NITRIC trial is a randomised, double-blind, controlled, parallel-group, two-sided superiority trial to be conducted in six paediatric cardiac surgical centres. One thousand three-hundred and twenty infants <2 years of age undergoing cardiac surgery with CPB will be randomly assigned to NO at 20 ppm administered into the CPB oxygenator for the duration of CPB or standard care (no NO) in a 1:1 ratio with stratification by age (<6 and ≥6 weeks), single ventricle physiology (Y/N) and study centre. The primary outcome will be VFD to day 28. Secondary outcomes include a composite of LCOS, need for extracorporeal membrane oxygenation or death within 28 days of surgery; length of stay in intensive care and in hospital; and, healthcare costs. Analyses will be conducted on an intention-to-treat basis. Preplanned secondary analyses will investigate the impact of NO on host inflammatory profiles post surgery.

Ethics and dissemination The study has ethical approval (HREC/17/QRCH/43, dated 26 April 2017), is registered in the Australian New Zealand Clinical Trials Registry (ACTRN1261700821392) and commenced recruitment in July 2017. The primary manuscript will be submitted for publication in a peer-reviewed journal.

Trial registration number ACTRN1261700821392

INTRODUCTION

Congenital heart disease (CHD) is the most common congenital condition, affecting around one in a hundred live born children. Up to 50% need cardiac surgery to correct the underlying abnormality at some stage during their life, with the majority of procedures requiring cardiopulmonary bypass (CPB). Substantial reductions in perioperative mortality in children following cardiac surgery have been achieved, and adult survivors of CHD now outnumber paediatric patients...
with CHD in most high-income countries. Despite these advances, major postoperative morbidity remains common and is associated with increased rate of long-term mortality, morbidity and disability. The exposure of host blood to large artificial organ surfaces combined with myocardial injury during surgery, results in a strong systemic inflammatory response of the host, which is further aggravated by reperfusion injury and the release of damage-associated molecular patterns during surgery. Postoperative LCOS is clinically defined by a need for inotropes to maintain end organ perfusion, an increased arterial-venous oxygen extraction, lactataemia and oliguria. LCOS may lead to multiorgan failure and a need for extracorporeal life support (ECLS). Several studies have shown that the presence and severity of LCOS, which affects 25%–40% of children post-CBP in the first hours following heart surgery, is strongly associated with postoperative morbidity and mortality. CPB-related side effects are most pronounced in infants and young children due to their higher metabolic requirement, altered inflammatory response and higher CPB circuit to patient blood volume. At the same time, this age group is particularly exposed to CPB during a vulnerable phase of brain development and remains at highest risk of suffering neuro- logical impairments due to acute brain injury occurring within the context of LCOS. Recent trials to reduce LCOS during cardiac surgery for CHD testing interventions such as steroids have not demonstrated consistent benefit. Given the adverse effects of CPB on early recovery and long-term neurodevelopment, there remains an urgent need for clinical trials evaluating novel therapies to address these problems.

Nitric oxide (NO) is an endogenous anti-inflammatory mediator and is essential to regulate endothelial function and microvascular inflammation. Several studies have demonstrated that exogenous NO can reduce myocardial damage in clinical and experimental settings of ischaemia and reperfusion. A previous small single-centre study in 16 children reported a reduction in bypass-induced inflammation using gaseous NO delivered at 20 ppm to CPB circuits. The duration of mechanical ventilation was significantly shorter (8.4 vs 16.3 hours; p<0.05) and so was intensive care unit (ICU) length of stay (53.8 vs 79.4 hours; p<0.05) in children receiving NO compared with the placebo group. We have previously reported the feasibility and safety of NO delivery to CPB in a single-centre randomised controlled pilot study in 198 infants and children (0–16 years) undergoing cardiac surgery. This pilot study demonstrated a statistically significantly lower proportion of children with LCOS in the intervention arm, a reduced requirement for ECLS and a trend to reduced length of stay, and shorter duration of mechanical ventilation. The effect was greatest in children under 2 years of age, with the greatest treatment benefit observed in children under 6 weeks.

Accordingly, we designed the NITRIC trial to test the primary hypothesis that, in infants under 2 years having cardiac surgery, using NO during CPB increases ventilator-free days (VFD) (the number of days patients spend alive and free from invasive mechanical ventilation up until postoperative day 28) compared with standard care. Here, we describe the NITRIC trial protocol.

METHODS

The NITRIC trial is a 1:2 patient multicentre, randomised, double-blind, standard care-controlled, parallel-group, trial in infants and children <2 years of age undergoing open heart surgery on CPB (figure 1).

### Study setting

Tertiary/quaternary paediatric cardiac surgical services in Australia and New Zealand, including Cardiac and Paediatric Intensive Care Services of Royal Children’s Hospital, Melbourne; Starship Children’s Hospital Auckland NZ; The Children’s Hospital at Westmead, Sydney; Princess Margaret Hospital for Children, Perth; and Queensland Children’s Hospital, Brisbane and Utrecht Medical Center, Utrecht, The Netherlands.

### Participants

Eligible children will be identified in the preoperative clinics, in the general cardiac wards or in the neonatal or paediatric intensive care unit (PICU). Included will be infants and children <2 years of age undergoing elective open heart surgery on CPB where consent of parents/guardian is obtained prior to surgery. The exclusion criteria relate to patient characteristics that will interfere with consent, with the intervention or with measurement of the primary and secondary outcomes. Inclusion and exclusion criteria are shown in table 1.
Table 1  Inclusion and exclusion criteria

<table>
<thead>
<tr>
<th>Patient group</th>
<th>Criterium</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inclusion</strong></td>
<td>Age</td>
<td>Postnatal age &lt;2 years.</td>
</tr>
<tr>
<td></td>
<td>Procedure</td>
<td>Open elective heart surgery.</td>
</tr>
<tr>
<td></td>
<td>Consent</td>
<td>Cardiopulmonary bypass used during surgery.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Parental/caregiver consent available prior to surgery.</td>
</tr>
</tbody>
</table>

| **Exclusion** | Age       | Age ≥2 years. |
|               | Procedure | Emergency cardiac surgery which may preclude obtaining informed consent (acutely required life-saving procedure in a patient unlikely to survive the next hours without the surgery). |
|               | Consent   | Heart surgery not requiring cardiopulmonary bypass. |
| Pulmonary hypertension |           | Persistently elevated pulmonary vascular resistance preoperatively receiving inhaled NO or preoperative intravenous use of drugs involved in the NO pathway such as glyceryl trinitrate within 48 hours prior to CPB (oral sildenafil treatment alone is not an exclusion). |

**Preoperative disease**
- ECLS immediately prior to surgery.
- Receiving ongoing treatment with antimicrobials for confirmed or suspected sepsis or septic shock diagnosed within 48 hours prior to the time of surgery.
- Treated with high doses of vasoactive drugs defined as a Vasoactive-Inotrope Score ≥15 within 24 hours prior to surgery.¹
- Cardiac arrest within 1 week (7 days) prior to surgery.
- Acute respiratory distress syndrome requiring high-frequency oscillatory ventilation within 48 hours prior to surgery.
- Chronic ventilator dependency (patients treated with non-invasive or invasive ventilation continuously for >28 days prior to cardiopulmonary bypass).
- Pre-existing methaemoglobinemia (>3%).


**Enrolment of patients undergoing repeated surgery during the first 2 years of life**

In order to assess the impact of the intervention on long-term outcomes, patients who were previously enrolled and randomised into the study who require a second or subsequent surgical procedure (such as patients with single ventricle physiology requiring a staged palliation) will undergo the same treatment allocation for subsequent surgeries requiring CPB, unless parents opt out. Patients who were not recruited into the study during their first procedure, but are scheduled for a subsequent procedure requiring CPB prior to their second birthday, will be eligible for recruitment.

**Randomisation and blinding**

Treatment assignment will be performed using a secure, centralised, web-based randomisation interface (Research Electronic Data Capture (REDCap), The University of Queensland). The allocation sequence will be generated by the study statistician using computer-generated random numbers using a variable block size stratified by age (<6 weeks, 6 weeks to 24 months), univentricular versus biventricular lesions, and by site. Of the investigating team, only the study perfusionist will be aware of the randomisation and NO delivery. Cardiologists, cardiac surgeons, anesthesiologists, intensivists, PICU nurses, research assistants, data analysts, and parents and caregivers will be blinded for the intervention. **Rationale for stratification:** the age group under 6 weeks represents the cohort at highest surgical risk. In the pilot study, the effect size of the NO delivery was greatest in these infants.²⁶ **Cardiac physiology (univentricular vs biventricular) is a major determinant of surgical complexity, risk and outcome.**¹³

**Blinding of the intervention**

Blinding arrangements in the operating theatre will be achieved by covering the NO delivery system with drapes. The dedicated study NO delivery system will be connected to the CPB oxygenator at all times, independent of randomisation. The family, surgeons, anaesthetists and PICU staff will be not aware of the treatment arm a patient is allocated to. The perfusionists will be advised that all aspects of CPB except for provision of NO (or not) should be performed according to standard institutional practice for study participants.

**Interventions**

Infants will be randomly assigned to NO or standard care. Those allocated to the NO arm will receive NO during CPB
blended into the fresh gas flow of the CPB oxygenator, which is kept at 3L/min. NO levels are maintained at 20 ppm using a NO delivery system (Ikaria INOmax DSIR, Ikaria, NJ, USA) or similar device. Continuous sampling of NO and NO\textsubscript{2} concentration will be undertaken from an access port before the oxygenator. NO will be started immediately when the patient is placed on CPB and ceased once weaned off CPB. Patients allocated to the standard study arm will receive the standard gas oxygen–air mix into the CPB oxygenator at a flow rate of 3L/min. If patients require several CPB runs during the same procedure, the study treatment will be provided for each CPB run using the same treatment allocation for every CPB run.

Relevant concomitant perioperative care
Arterial partial pressures of CO\textsubscript{2} will be maintained constantly in both study arms as per institutional practice (following each centre’s protocols on alpha/pH stat and temperatures). The FiO\textsubscript{2} of the fresh gas flow will be set between 21% and 100%, according to centre-specific CPB protocols. Techniques of anaesthesia and surgery will not be specified to allow site-specific individual practice. The decision whether a patient requires treatment with inhaled NO (iNO) into the ventilator circuit prior to, during or after CPB remains at the discretion of the treating physicians (anaesthetists, cardiac surgeons or intensivists) independent of treatment allocation. The postoperative care and decisions on inotropes and other vasoactive drug delivery, fluid management, renal replacement therapy, iNO therapy or indication for ECLS will be performed as per site-specific standard protocols of care.

Study outcomes
The primary outcome is VFD for the first 28 days postrandomisation (table 2). The primary outcome will be measured using duration of invasive respiratory support for all episodes with an endotracheal tube in situ for the first 28 days postrandomisation. A systematic zero value will be assigned for patients who die to weigh death as the most pejorative outcome. Treatment with non-invasive ventilation and high-flow nasal cannulae will not be considered as ventilator days. Secondary outcomes are defined as the composite outcome compromising LCOS, need for postoperative ECLS or 28-day mortality; ICU and hospital length of stay; and healthcare costs. In addition, the long-term outcome of patients will be followed up at 12 months postprocedure.

Low cardiac output syndrome
LCOS\textsuperscript{10} is defined as a blood lactate level >4mmol/L with an oxygen extraction of >35% (SaO\textsubscript{2}–ScvO\textsubscript{2} gradient >35%) within the first 48 hours postoperatively, or a high inotrope requirement defined as Vasoactive-Inotropic Score ≥15.\textsuperscript{28 29}

Rationale for primary and secondary outcomes
VFD represents one of the strongest predictors of short-term and long-term outcomes,\textsuperscript{30} including length of ICU stay, morbidity (impaired neurodevelopment, hospital-acquired infections) and mortality. VFD directly reflect intensive care resource use and healthcare costs.\textsuperscript{30} VFD fulfils Specific, Measurable, Achievable, Realistic and Timely criteria. LCOS is directly related to VFD, as infants usually do not tolerate weaning or fail extubation if LCOS and organ dysfunction have not resolved. The composite of LCOS, ECLS use and mortality as a secondary end point, is a strong patient-centred outcome and directly relates to the intervention in terms of biological plausibility.

Adverse events
It is recognised that the postoperative paediatric cardiac surgical patient population will experience a number of common aberrations in laboratory values, signs and symptoms due to the severity of the underlying disease and the impact of standard therapies. Intensive care patients will frequently develop life-threatening organ failure(s) unrelated to study interventions and despite optimal management. Therefore, consistent with established practice in academic ICU trials,\textsuperscript{31} events that are part of the natural history of the primary disease process or expected complications of critical illness will not be reported as serious adverse events in this study. All adverse events which are considered to be potentially causally related to the study intervention or are otherwise of concern in the investigator’s judgement will be reported unless they are prespecified study outcomes. Specific adverse events related to NO delivery during CPB include air embolism, severe hypotension during bypass and increased methaemoglobinemia (>3%). Of note, in previous studies, methaemoglobin values using NO at 20 ppm were similar in both the control and intervention groups (1.4%).\textsuperscript{25 26} Events that are collected as study outcomes will not be reported as adverse events.

Safety data monitoring
The Data Safety Monitoring Board (DSMB) consists of a general and a cardiac paediatric intensivist, a cardiac surgeon and a statistician. None of the DSMB members will be involved in recruitment of study patients at their site. DSMB members will not be supervised by any study investigator or participate as investigators in any study currently under review by this DSMB. The primary objective of the DSMB is to monitor the safety of the intervention and the validity and integrity of the data from the NITRIC study. Additionally, the DSMB will evaluate the pace of recruitment and will make recommendations to the NITRIC Chief investigator(s) and Steering Board regarding the continuation, modification or termination of the study. The DSMB will evaluate on an ongoing basis, the accumulating safety assessments to ensure the ongoing safety of study subjects. The DSMB will meet via teleconference call after recruitment of 660, and of 1000 children, respectively, and on trial completion.

The DSMB can request unblinding in the event of a serious adverse event defined as a cardiac arrest, need for ECLS, or other incident leading to permanent harm considered to be likely related to the study intervention.
A pilot study of 134 patients aged <2 years showed a 2.74 days (66 hours) increase in VFD associated with the study intervention.26 This includes patients who died, who were considered as zero VFDs. The VFD increase associated with the intervention represents an effect size of 0.33 SD based on a SD of 8.1 days in the pilot study control group. Based on the primary outcome measure VFD, 1320 patients (660 per group) will be required to demonstrate a significant increase in VFD assuming a minimally clinically significant effect size (0.2 SD; 1.66 days or 40 hours), 90% power, two-sided alpha level of significance of 5%, 10% withdrawals and 15% increase in sample size to account for a non-normal distribution of VFD. In Australia and New Zealand, ~800 of children <2 years of age undergo surgery for a congenital heart defect requiring CPB each year, including patients with multiple procedures. The consent rate of eligible patients was 78% in the pilot trial.26 With an expected conservative estimate 60% enrolment rate of eligible patients, we expect a 3.5-year recruitment period for the study.

**Sample size**

**Data collection, management and analysis**

**Data collection**

Baseline variables (demographics, primary cardiac diagnosis, comorbidities including syndromes), preoperative disease
severity, surgical data (length of CPB and cross-clamp, type of surgery and complexity score, other CPB characteristics, blood product usage), primary end points, secondary end points, predetermined physiological variables of interest and process of care measures will be prospectively recorded into a study REDCap online database. Plausibility and range checks are implemented. Paired arterial and venous gases will be collected postoperatively at 0, 6, 12, 24 and 48 hours (in PICU until discharge to the ward or removal of arterial and central venous lines, whichever occurs first) to assess for lactate and SaO2-ScvO2 gradient. Key physiological and blood parameters and Paediatric Logistic Organ Dysfunction-2 scores will be measured at 0, 6, 12, 24 and 48 hours postadmission or until PICU discharge whichever occurs earlier. Delayed chest closure, use of iNO and duration of circulatory, renal and ventilatory support postoperatively will be recorded. Gross functional performance assessment will be recorded on admission to PICU and on discharge from hospital. Neurological and functional outcome (including phone interviews with parents/caregivers) will be assessed at 12 months postoperatively using Ages and Stages Questionnaires and assessment of quality of life using paediatric quality of life inventory. Details on the long-term follow-up will be published separately.

Biobanking
Blood markers for myocardial injury and inflammatory response will be collected on induction of anaesthesia (baseline—prebypass), at admission to PICU (0 hours—postbypass) and at 12, and 24 hours, in patients where parents consent to biobanking. Blood will be collected presurgery as preoperative baseline (before onset of cardiac surgery, done by the anaesthetist during the induction of the patient once the arterial line has been inserted): 1–2 mL of EDTA blood (for DNA), 2.5 mL of PAXgene blood (for gene expression markers), 1–2 mL of serum; and postoperatively at 0, 12 and 24 hours (in PICU until discharge to the ward): 2.5 mL of PAXgene blood (time point 0), and 1–2 mL of serum. The samples will be processed, stored and shipped according to accepted international standards and batch analysed.

The investigators are responsible for ensuring the accuracy, completeness, legibility and timeliness of the data reported. The investigators will maintain adequate case histories of study participants, including accurate case report forms (CRFs), and source documentation. Data will be prospectively entered into a secure web-based database (REDCap; https://redcap.health.uq.edu.au/), hosted by the University of Queensland. Printed paper CRFs will be available if required. All study information and documentation will be securely stored for a period of 15 years after the date of the child’s 18th birthday.

**Statistical analysis plan**

**Analysis plan**
Analyses will apply the intention-to-treat principle. Descriptive statistics will be used to describe baseline characteristics of the study cohort and each subgroup by treatment group. The primary outcome measure will be analysed using a Mann-Whitney U test as VFD is non-normally distributed variable. Analysis of secondary outcomes includes both comparisons of measurements and proportions, using CIs of differences as the major method of presentation where possible, otherwise standard techniques such as Mann-Whitney U tests, t-tests and $\chi^2$ tests will be utilised. Survival outcomes will be compared between treatment groups using Kaplan-Meier product limit method and log-rank test. Statistical significance will be set at the 0.05 level for the primary outcome.

A safety and efficacy interim analysis after 660 (the half-way point), and after 1000 enrolled patients will be performed by an independent statistician to evaluate for safety endpoints, to assess the predictive probability of reaching the study goals and compare VFD between treatment groups. Consideration to stopping the trial early by an independent DSMB will be based on safety concerns, futility or strong evidence of a difference between groups for VFD (based on a Haybittle-Peto boundary $p=0.001$).

A detailed analysis plan specifying statistical analyses including health economic analyses will be placed in the public domain prior to recruitment of the last participant.

**Biomarker measurements**
Nestled substudies will be performed in selected samples at sites performing biobanking (1) to test the impact of the intervention on markers of systemic and myocardial inflammation, (2) to compare treatment response between patients depending on preintervention severity assessed by markers of inflammation and organ failure and (3) to biochemically define responders to the intervention (to identify patient subgroups prerandomisation that are more likely to respond to a specific treatment). The use of samples/data will be governed by the study steering board and resulting publications must appropriately acknowledge the study. Combining a large RCT with a nested biobank is recommended to maximise scientific knowledge.

**Health economic evaluation**
A within trial economic evaluation will be used to determine if providing NO is cost-saving compared with usual care from the health system perspective. A comprehensive cost-effectiveness analysis will be undertaken to determine the level of cost savings (if any). Length of stay (in PICU and in non-intensive stay) will be the main outcome variable. Resources used before first discharge will be compared between treatments. Resources will subsequently be costed, based on hospital cost centre or standard national sources (eg, Independent Hospital Pricing Authority).

**Monitoring**
The study leadership team is responsible for 100% monitoring of investigator and study nurse credentials, training records and delegation of responsibility logs, and will review 100% of consent forms. CRFs will be compared with source documentation to ensure data are accurate.
and complete. One hundred per cent of source data verification of eligibility criteria and the primary outcome and the composite secondary outcome of LCOS, ECLS or death will be performed. An independent monitoring per each site will monitor the data fields required for eligibility, primary and secondary study endpoints, and serious adverse events (SAEs) using primary source verification. In addition, site visits and regular monitoring of the blood sample storage will be performed.

Patient and public involvement
Consumers and the public were consulted to design a video informing parents about the study. Patients and the public had no other involvement in study design.

Ethics
This protocol and the informed consent document and any subsequent modifications have been reviewed. This study will be conducted in compliance with the current version of the protocol. Any change to the protocol document or informed consent form that affects the scientific intent, study design, patient safety, or may affect a participants’ willingness to continue in the study is considered an amendment, and therefore will be written and filed as an amendment to this protocol and/or informed consent form. All protocol deviations must be recorded in the patient record (source document) and on the CRF and must be reported to the principal investigator (PI). Protocol deviations will be assessed for significance by the PI.

Consent will be sought from the parents of every child <2 years of age undergoing CPB for elective cardiac surgery over the study period. When the family is seen by the surgeons in preassessment clinic (usually days prior to surgery), the study will be mentioned to them by the surgeon. In addition, the study team will provide study information prior to hospitalisation to families, including printed study flyers, and links to online study documentation (media release). Participant confidentiality is strictly held in trust by the participating investigators, research staff and the sponsoring institution and their agents. The study protocol, documentation, data and all other information generated will be held in strict confidence.

Significance
Postoperative paediatric cardiac surgical patients have a high consumption of intensive care resources and remain at very high risk of major complications, including cardiac arrest, death and long-term neurological impairment. Approximately 10% of children with CHD survive with major neurological sequelae postoperatively, resulting in a massive lifelong burden for patients, families, health-care systems and the society. An attempt to reduce LCOS and hence perioperative morbidity has the potential to translate not only to a reduction in intensive care resource utilisation but also to impact positively on long-term outcomes. Side effects from heart surgery for CHD translate into long-term morbidity, persisting into adult life with a major impact on other family members and society. This study will deliver the high-level randomised evidence with the potential to show a reduction in post-operative morbidity and mortality in children with CHD.

Author affiliations
1Paediatric Critical Care Research Group, Child Health Research Institute, The University of Queensland, Brisbane, Queensland, Australia
2Paediatric Intensive Care Unit, Queensland Children’s Hospital, Children’s Health Queensland, Brisbane, Queensland, Australia
3Cardiac Surgical Unit, Royal Children’s Hospital, Melbourne, Victoria, Australia
4Faculty of Medicine, Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia
5Murdoch Children’s Research Institute, Melbourne, Victoria, Australia
6Paediatric Intensive Care Unit, Starship Children’s Hospital, Auckland, New Zealand
7Paediatric Critical Care, Perth Children’s Hospital, Western Australia and The University of Western Australia, Crawley, Western Australia, Australia
8Kids Critical Care Research, Paediatric Intensive Care Unit, Children’s Hospital at Westmead, Westmead, New South Wales, Australia
9Sydney Children’s Hospital Network, Sydney, New South Wales, Australia
10Department of Cardiac Surgery, Royal Children’s Hospital, Melbourne, Victoria, Australia
11Heart Research, Murdoch Childrens Research Institute, Melbourne, Victoria, Australia
12Department of Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia
13School of Medicine, Children’s Health Clinical Unit, University of Queensland, Brisbane, Queensland, Australia
14Cardiac Surgery, Queensland Children’s Hospital, Brisbane, Queensland, Australia
15Heart Centre for Children, The Children’s Hospital at Westmead, Westmead, New South Wales, Australia
16Sydney Children’s Hospital Network and Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia
17Paediatric Intensive Care Unit, Royal Children’s Hospital Melbourne, Melbourne, Victoria, Australia
18Division of Anaesthetics, University Medical Center Utrecht, Utrecht, The Netherlands
19Centre for the Business and Economics of Health, The University of Queensland, Brisbane, Queensland, Australia
20The Infection and Inflammation Group, The University of Queensland Diamantina Institute, The University of Queensland, Translational Research Institute, Brisbane, Queensland, Australia
21The Intensive Care Research Programme, Medical Research Institute of New Zealand, Wellington, New Zealand
22School of Public Health, Bond University, Gold Coast, Brisbane, Australia

Acknowledgements
The authors would like to thank the parents and children participating in this trial and the medical and nursing and research teams in the participating sites for their help in study setup, recruitment, data collection and monitoring of study data.

Collaborators

Contributors
The study protocol first draft was designed by LJS and AS based on the previous pilot study design established by SBH and WB. MJ wrote the section.
REFERENCES